anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a pH responsive polymer made with mono-[2-(methacryloyloxy)ethyl]phthalate and/or mono-[2-(methacryloyloxy)ethyl hexahydro]phthalate. Also disclosed is an aqueous coating composition including at least one latex polymer derived from at least one monomer copolymerized or blended with alkali swellable acrylate copolymer. Also provided is an aqueous coating composition including at least one latex polymer derived from at least one monomer blended with alkali swellable acrylate copolymer, at least one pigment, and water. Also provided is a method of preparing an aqueous coating composition such as a latex paint including the above components. Also provided are methods of preparing mono-[2-(methacryloyloxy)ethyl]phthalate. Also provided are compositions and methods using the polymer in hydraulic fracturing, personal care and or home and industrial cleaners.
The study is aimed at determining the effects of ROOD's sensory motor training along with constraint induced movement therapy in sub-acute stroke and is being conducted in National Institute of Rehabilitation Medicine Islamabad and Pakistan Railway General Hospital, Rawalpindi (Feb 2019-July 2019). Sample size of the study is 36 patients, 36 were included in the study on the basis of inclusion criteria, 18 for each group. Patients were allocated randomly and equally in each group. Similar conservative rehabilitation protocol was designed for both control and experimental group except for experimental group had ROOD's sensory motor training and CIMT training. Patients were examined at 1st visit before administration of any treatment and at 6th week which was also the last one (after completing 6 weeks sessions at alternate days). Baseline evaluation for demographics and assessment was taken. Fugyl-meyer assessment scale(FMA) and Wolf motor function test(WMFT) as measuring tools were used for first and 6th week assessment. 29 patients completed the study while 4 patient from control group and 3 patients from experiment group were lost to follow up and were considered drop outs.
Hether to unknown metabolically inert classical folate analog inhibitors of the enzyme Dihydrofolate Reductase [DHFR] that are transported to tumor cells via the reduced folate receptors are provided. These compounds exhibit superior anti-asthmatic responses in rabbits relative to methotrexate and the standard drug theophylline. The title compound 4-amino-4-deoxy-5,8,10-trideaza-pteroyl-4'-methyleneglutamic acid (1) exhibited outstanding anti-tumor activity. Compound 1 was 1,000 to 10,000 times more active than methotrexate in causing total growth inhibition (TGI) of a number of human tumor cells in culture. Unlike methotrexate the the TGI values of 1 are in the range of therapeutically relevant concentrations. Tumor cells that are resistant to methotrexate by virtue of defective polyglutamylation were 3-4 times more collaterally sensitive to compound 1. 1 was completely inert on incubation with folylpolyglutamate synthetase. On treatment of 1 with a preparation of aldehyde oxidase no oxidative activity was uncovered. Compound 1 was totally resistant to hydrolytic cleavage of the glutamate moiety by carboxypeptidase derived from Pseudomonad sp. These biochemical and pharmacological properties of the metabolically inert classical antifolates establish their clinical utility and superiority as new and novel anti-inflammatory and anti-tumor agents exhibiting enhanced target enzyme specificity and lower toxicity.
All participants will receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
PURPOSE:To obtain the subject substance having antiretrovirus and human immunodeficiency virus(HIV) growth inhibitory action by reacting amphotericin B with a sulfonating agent. CONSTITUTION:Amphotericin B is dissolved in pyridine and a sulfur trioxide- pyridine complex is added thereto. Pyridine is then added and the resultant mixture is stirred at 60-65 deg.C for 6hr. After cooling, the supernatant liquid is removed to dissolve the residue in water. A strong acidic ion exchange resin is added to stir the resultant mixture. The obtained insoluble substances are filtered off and the filtrate is regulated to pH5.5 with an aqueous solution of barium hydroxide and then to pH7.5 with powdery barium carbonate. Active carbon is subsequently added thereto and insoluble substances are filtered off using Celite(R). A strong acidic ion exchange resin is then added to stir the resultant filtrate. Insoluble substances are subsequently filtered off. The obtained filtrate is then regulated to pH7.3 with an aqueous solution of sodium hydroxide and subsequently concentrated. Active carbon is then added to filter off insoluble substances. The resultant filtrate is subsequently freeze-dried to afford the objective potassium salt of amphotericin B sulfonating agent reaction product.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data reflect exposure to Tazarotene Foam in 744 subjects with acne vulgaris. Subjects were aged 12 to 45 years and were treated once daily in the evening for 12 weeks. Adverse reactions reported in ≥ 1% of subjects treated with Tazarotene Foam are presented in Table 1. Most adverse reactions were mild to moderate in severity. Severe adverse reactions represented 3.0% of the subjects treated. Overall, 2.7% (20/744) of subjects discontinued Tazarotene Foam because of local skin reactions.

Additional adverse reactions that were reported in <1% of subjects treated with Tazarotene Foam included application site reactions (including discoloration, discomfort, edema, rash, and swelling), dermatitis, impetigo, and pruritus.

Local skin reactions, dryness, erythema, and peeling actively assessed by the investigator and burning/stinging and itching reported by the subject were evaluated at baseline, during treatment, and end of treatment. During the 12 weeks of treatment, each local skin reaction peaked at Week 2 and gradually reduced thereafter with the continued use of Tazarotene Foam.
Dexamethasone 10 mg iv on day 1 and day 2, then 5 mg iv on day 3. For the patients the serum total bilirubin did not decrease to 1.5 ULN, then 5 mg iv on day 4.
Due to the poor prognosis of diffuse intrinsic pontine gliomas, the limited therapy options, the relevant portion of EGFR expression and the unexpected good response to the therapy with OSAG 101 in the phase II study, a phase III study was planned in newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. A phase II study in patients of recurrence/resistance high grade glioma in childhood or adolescence showed that, in particular, a part of the intrinsic pontine glioma response to the monotherapy with OSAG 101 resulting in a reduction in the size of the tumour or stabilisation in the growth of the tumour. Together with clinical improvement, stabilisation lasted markedly over 6 months in two thirds of the patients. The current phase III study was scheduled to provide evidence of the effectiveness in the case of newly diagnosed intrinsic pontine glioma. In this study, OSAG 101 will be given concomitantly to the only standard therapy for this kind of tumour, i.e. the fractionated radiotherapy, to show effectiveness in the primary endpoint of median progression-free survival, the secondary endpoint of median overall survival and the side effect profile.

Evidence from the median progression-free survival and the side effect profile of this combination met the expected results and one may consider that combination therapy of this therapeutic approach with other immunotherapeutic or antiangiogenic approaches and/or mild chemotherapy could lead to a better prognosis and quality of life for these patients.
OBJECTIVES: I. Compare the overall and relapse free survival of patients with stage II or III rectal cancer treated with one of the following three regimens: bolus injections of fluorouracil (5-FU) prior to and following pelvic irradiation plus protracted venous infusion (PVI) 5-FU radiosensitization vs PVI 5-FU prior to and following pelvic irradiation plus PVI 5-FU radiosensitization vs bolus 5-FU with leucovorin calcium and levamisole prior to and following pelvic irradiation. II. Describe relapse patterns and tolerance associated with these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to type of prior surgery (abdominoperineal resection vs anterior resection), nodal status (N0 vs N1 vs N2-3), depth of tumor invasion (T1-2 vs T3 vs T4a vs T4b), time from surgery to study entry (20-45 days vs 46-70 days), participating center, and performance status (0-1 vs 2). Patients are randomized to one of three treatment arms. Arm I: Patients receive fluorouracil (5-FU) IV on days 1-5 and 29-33. 5-FU is then given as a continuous infusion beginning on day 57 and continuing concurrently with radiotherapy for 5 weeks. Following a 28 day break from treatment patients receive 5-FU IV on days 1-5 of a 28 day course. Postradiotherapy treatment repeats for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive 5-FU IV continuously on days 1-42. 5-FU and radiotherapy are then administered as in arm II. Arm III: Patients receive leucovorin calcium (CF) IV followed by 5-FU IV on days 1-5 and 29-33. Patients also receive oral levamisole twice daily on days 1-3, 15-17, 29-31, and 43-45. CF IV and 5-FU IV are then given on days 57-60 and 85-88 concurrently with radiotherapy. Following a 28 day break from treatment patients receive CF IV and 5-FU IV on days 1-5 and 29-33 and oral levamisole twice daily on days 1-3, 15-17, 29-31, and 43-45 in the absence of disease progression or unacceptable toxicity. All patients receive radiotherapy 5 days per week for 5 weeks starting on day 57. Patients are followed every 4 months for 2 years, then every 6 months for 4 years, and then annually until death.

PROJECTED ACCRUAL: A total of 1,800 patients (600 per arm) will be accrued for this study.
Endoscopy-related injuries (ERI) occur frequently, emphasizing the crucial need to integrate ergonomic principles into endoscopic practice to mitigate risks and prioritize the health and well-being of endoscopists. Checklists are a proven strategy in healthcare behavior modification; however, the efficacy of a pre-procedure ergonomic timeout checklist remains underexplored. To bridge this gap, the aim is to evaluate the effectiveness and implementation of the Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE-E) bundle-a multicomponent intervention comprised of a pre-procedure ergonomic timeout checklist and evidence-based implementation strategies-as a strategy to mitigate the risk of ERI during colonoscopy.

Conducted will be a Hybrid Type 2 cluster randomized controlled trial across 10 endoscopy units in North America with 100 participants. Units will be randomized to the SCOPE-E bundle or usual practice. Effectiveness will be measured by comparing Rapid Entire Body Assessment (REBA) scores before and 3 months after implementation between intervention and control groups. Simultaneously, implementation outcomes will be assessed to understand the practicality of this ergonomic intervention and inform widescale adoption. If demonstrated to be effective, the SCOPE-E Bundle is a feasible and cost-effective intervention that holds significant promise for improving ergonomics globally.
FIELD: polymers. SUBSTANCE: invention relates to biodecomposing and biocompatible compositions with memory of own form. PLG2000, PDS1300, PLGA2000 or PDC40 are examples of such polymers. These polymers can be used in medicinal articles and as carriers of therapeutic or diagnostic agents. EFFECT: expanded arsenal of agents and articles of claimed desirnation. 27 cl, 8 dwg, 15 tbl
PURPOSE:To provide the title compsn. which is useful as a base for cosmetic and medicine, has excellent extensibility and if free from retention of wetness to the touch and which comprises a cyclic dimethylpolysiloxane as a principal agent and, blended therewith, a mixture of at least one member selected from among animal and vegetable oils and vaselines and a dextrin aliph. acid ester. CONSTITUTION:90-30pts.wt. cyclic dimethylpolysiloxane (A) of formula I (wherein n is 4-6) [e.g., decamethylcyclopentasiloxane (b.p. 210 deg.C; viscosity 3.9cs/25 deg.C)], 5-50pts.wt. mixture (B) of at least one member selected from among animal and vegetable oils such as jojoba oil, soybean oil, lanolin and beef tallow and vaselines, and 5-30pts.wt. dextrin aliph. acid ester (C) of formula II (wherein R is H or an 8-20C acyl; and m is 20-30) are mixed together, heated so as to form a homogeneous soln., and quenched, thus giving a gel.
BACKGROUND: Slow pathway elimination of the atrioventricular node (AVN) is essential to treat AVN reentrant tachycardia (AVNRT). However, injury to the AVN conduction (IAVN) is one of the serious complications. Cryofreezing energy is expected to reduce the incidence of IAVN. This study aimed to investigate the usefulness of a novel method to avoid IAVN during cryoablation of AVNRT.
METHODS: A total of 157 patients (average age, 65.8 years; male, 71) suffering from AVNRT were included. Once the AVNRT terminated during cryo-ablation, then rapid atrial constant pacing (RACP) was performed during freezing at a rate lower 10 bpm than that inducing Wenchebach AV block in 74 (47.1 %) patients (Group A). The RACP rate was decreasingly reduced by 10 bpm in case of the occurrence of IAVN. When the RACP reached 100 bpm, the cryoablation was prematurely terminated. Group B patients (83 = 52.9 %) underwent cryoablation during sinus rhythm. All patients were allocated in a randomized fashion. We compared the severity of the IAVN between Groups A and B.
RESULTS: There were no significant differences at 12 months regarding the freedom from the AVNRT between Groups A and B. However, the duration of the IAVN was significantly longer in Group B than A (p = 0.02). There were no significant differences regarding the distance between the His recording sites and successful ablation sites between Groups A and B. No permanent IAVN requiring pacemaker implantation was provoked in either group.
CONCLUSION: RACP was useful to avoid sustained and serious IAVN during cryoablation of AVNRT.
The invention encompasses therapeutic compositions including Globo H-KLH conjugates and/or therapeutic antibodies as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular the therapeutic conjugates include a Globo H moiety and a KLH moiety and/or a derivatized KLH moiety subunit optionally linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. An effective immune response is one that reduces the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality. 1 of 134 an Li.. cm o~. C t V <4-K o 4 (9 -2 z S -' 0 2' cc t -~ m > an a -r a. N. S a 7 ______________________ LI
For the clusters (health posts) in this arm, the health worker will prick the finger of the eligible patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained which will be added to specimen dilution buffer and the dipstick will be placed into the diluted sample. It will be removed after the liquid rises and the timer will be started and result will be interpreted in 5 minutes. Interpretation of CRP levels: Only red color line (No blue line): \<10 mg/L One blue line: 10-40 mg/L Two blue lines: 40-80 mg/L Three blue lines: \>80 mg/L. CRP levels of 40 mg/L or above will be considered as increased CRP levels. The decision on antimicrobial use and other treatments will be made with the help of CRP results in addition to information obtained from the history and physical examination.
Subjects will be maintained on oral zolmitriptan dose 3. Cocaine will be administered acutely during zolmitriptan dose 3 maintenance. Placebo will be administered acutely during zolmitriptan dose 3 maintenance.
Participants in HIIT group underwent 3 sessions per week for 12 weeks. The HIIT protocol (maximum 60 cycles per 20-minute session) includes 8-second fast pedaling (approximately 80% of maximum heart rate (HR max)) followed by slow pedaling (20-30 rpm) for 12 seconds. To facilitate acceleration and limit the stagnation of the bicycle wheel, the selected resistance was very low (almost zero).
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular to ophthalmology and deals with treatment of dystrophic diseases of posterior eye pole. For this purpose dissection of conjunctiva and separation of Tenon's capsule to posterior eye pole are performed. Into area of optic nerve successively introduced are 10% solution of trichloroacetic acid and crystalline talc. After 10-14 days into area of optic nerve retrobulbarly introduced are 0.5-0.8 ml of suspension of autologous macrophages, obtained from monocytes of patient's peripheral blood, in concentration (1.5-6.5)ù106 live cells/ml. Procedure of macrophage suspension introduction is repeated after three and six months. ^ EFFECT: method increases treatment efficiency due to improvement of blood circulation in area of posterior eye pole with stimulation of reparative processes in affected optic fibres. ^ 3 cl, 2 ex
The invention relates to a galenical technique domain, particularly relates to a latex product of plant combination for improving the sexual disorder and preparation method thereof . The said plant latex product is composed of fragrant plant extract, plant auxiliary agent, plant emulsifier and water solution. In addition, the invention also provides a preparation method thereof. Based on the features of sexual function, the up and down assembled plant emulsifier used concomitantly for improving impotency and frigidity symptoms such as impotence and coldness of the genitals is respectively formed. The liquid supply method combining upwelling to nasal cavity with downwelling to sexual organs is used for the first time to realize synergistic reaction furthermore to increase curative effect. The latex product is upwelled nasal cavity and downwelled to sexual organs before sexual intercourse, therefore it can strength yang, nourish yin, stimulate the oestrous behaviour.
The American Pharmacists Association (APhA) Foundation has partnered with a federally qualified health center (FQHC), a supermarket community pharmacy, and an accountable care organization (ACO) to participate in this ABM for ACO Beneficiaries initiative. The FQHC, El Rio Community Health Center pharmacy, and supermarket pharmacy, Fry's Pharmacy, will serve as implementing pharmacy study sites and will implement the ABM for beneficiaries of the ACO who utilize their pharmacies for medication refill services. The ABM involves synchronizing all medications to come due on the same day of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes. The ACO will provide medical and claims data on enrolled subjects as well as a control group for the intervention population. The APhA Foundation will aggregate intervention, prescription fill, and economic data from the 3 partners in an effort to evaluate the impact of the ABM on healthcare costs and medication adherence. The APhA Foundation has an a priori intent to publish the project results.
Medical students receive a 30 minutes hands-on training session. All study probands perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
PURPOSE:A novel oily beautifying cosmetic, uniform, transparent, liquid, showing improved stability and good beautifying effect in use, obtained by dissolving a fatty acid ester of ascorbic acid using an esterification product of a glycerol condensate and a higher fatty acid. CONSTITUTION:0.1-5wt%, preferably 1-3wt% fatty acid ester of ascobric acid (ascobic acid monosterate, etc.) is dissolved in an esterification product (especially this esterification product is a partial ester, preferably has two or more remaining unreacted OH groups in one molecule on average) of a glycerol condensate (e.g., diglycerol, etc.) and >=8C higher fatty acid (e.g., isostearic acid, etc.), to give a transparent oily beautifying cosmetic. The cosmetic may be blended with olive oill, avogado oil, squalan, isopropyl myristate, oleyl alcohol, etc. besides the above-mentioned components. EFFECT:Having good feeling, providing water repellency.
This is a phase 2 multi-center, double-blind, placebo-controlled study of the efficacy and safety of nitazoxanide for the treatment of solid organ and hematopoietic stem cell transplant recipients with symptomatic diarrhea due to Norovirus. The study involves a total of 160 Hematopoietic Stem Cell or Solid Organ transplant recipients, equal to or greater than 12 years of age with diagnosis of Norovirus who will be selected and randomly assigned (1:1) into two treatment groups: nitazoxanide or placebo. The study duration is approximately 60 months and subject participation duration is approximately 6 months. Given the safety of prolonged therapy with nitazoxanide, lack of interactions with common post-transplant medications, putative antiviral activity and prolonged duration of viral shedding we are assessing 56 doses of therapy. The longitudinal monitoring phase will provide useful information on the course of host and viral responses in subjects with chronic Norovirus infection with and without treatment. Randomization will be stratified by age group (pediatric (12 through 17 years) vs. adult (greater than or equal to 18 years)), chronicity of Norovirus-associated symptoms (acute (less than 14 days) vs. chronic (greater than or equal to 14 days)) and transplant type (solid organ (SOT)) vs. hematopoietic stem cell transplant (HSCT)). Enrolled subjects will participate in 2 phases of the study: Treatment Phase, which will include dosing with the assigned study agent for 28 days. Longitudinal Monitoring Phase which will include telephone call on Days 35, 53, 113, 173. Primary objective is 1) to assess the clinical efficacy of nitazoxanide for the management of acute and chronic Norovirus in transplant recipients. Secondary Objectives are 1) to assess the virologic efficacy of nitazoxanide and 2) to assess the safety of nitazoxanide for the management of acute and chronic Norovirus in transplant recipients.